Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: Relationship to type and tumour behaviour

Endocrine-Related Cancer

Volumn 13, Issue 3, 2006, Pages 931-944

  Garcia De La Torre, N ^a   Buley, I ^b,c   Wass, J A H ^a   Turner, H E ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c TORBAY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; FIBROBLAST GROWTH FACTOR 2; GLYCOPROTEIN; GROWTH FACTOR; LYMPHATIC VESSEL ENDOTHELIAL RECEPTOR 1; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN C;

ADENOMA; ADOLESCENT; ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; FEMALE; FOLLICULAR CARCINOMA; GRAVES DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPH VESSEL ENDOTHELIUM; LYMPHADENECTOMY; LYMPHANGIOGENESIS; MAJOR CLINICAL STUDY; MALE; MEDULLARY CARCINOMA; METASTASIS; NODULAR GOITER; PAPILLARY CARCINOMA; PHENOTYPE; PROGNOSIS; PROTEIN EXPRESSION; THYROID CARCINOMA; THYROIDECTOMY; TOXIC GOITER; TUMOR VASCULARIZATION; TUMOR VOLUME; VASCULAR ENDOTHELIUM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FIBROBLAST GROWTH FACTOR 2; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHANGIOGENESIS; LYMPHATIC VESSELS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; THYROID NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33751095944     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.01210     Document Type: Article

References (45)

1. Akslen LA & Livolsi VA 2000 Increased angiogenesis in papillary thyroid carcinoma but lack of prognostic importance. Human Pathology 31 439-342.
2. Bernini GP, Moretti A, Bonadio AG, Menicagli M, Viacava P, Naccarato AG, Iacconi P, Miccoli P & Salvetti A 2002 Angiogenesis in human normal and pathologic adrenal cortex. Journal of Clinical Endocrinology and Metabolism 87 4961-4965.
3. Boelaert K, McCabe CJ, Tannahill LA, Gittoes NJL, Holder RL, Watkinson JC, Bradwell AR, Sheppard MC & Franklyn JA 2003 Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism 88 2341-2347.
4. Brem SS, Gullino PM & Medina D 1978 Angiogenesis as a marker of preneoplastic lesions of the human breast. Cancer 41 239-244.
5. Bunone G, Vigneri P, Mariani L, Buto S, Collini P, Pilotti S, Pierotti MA & Bongarzone I 1999 Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. American Journal of Pathology 155 1967-1976.
6. Cowles AL, Borgstedt HH & Gillies AJ 1971 Tissue weights and rates of blood flow in man for the prediction of anesthetic uptake and distribution. Anesthesiology 35 523-526.
7. Eggo MC, Hopkins JM, Franklyn JA, Johnson GD, Sanders DS & Sheppard MC 1995 Expression of fibroblast growth factors in thyroid cancer. Journal of Clinical Endocrinology and Metabolism 80 1006-1011.
8. Esser S, Wolburg K, Wolburg H, Breier G, Kurzchalia T & Risau W 1998 Vascular endothelial growth factor induces endothelial fenestrations in vitro. Journal of Cell Biology 140 947-959.
9. Fellmer PT, Sato K, Tanaka R, Okamoto T, Kato Y, Kobayashi M, Shibuya M & Obara T 1999 Vascular endothelial growth factor-C gene expression in papillary and follicular thyroid carcinomas. Surgery 126 1056-1062.
10. Fenton C, Patel A, Dinauer C, Robie DK, Tuttle RM & Francis GL 2000 The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults. Thyroid 10 349-357.
11. Ferrara N & Bunting S 1996 Vascular endothelial growth factor, a specific regulator of angiogenesis. Current Opinion in Nephrology and Hypertension 5 35-44.
12. Folkman J 1989 What is the evidence that tumors are angiogenesis dependent? Journal of the National Cancer Institute 82 4-6.
13. Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC & Harris AL 1995 Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. Journal of Patholology 177 275-283.
14. Hall FT, Freeman JL, Asa SL, Jackson DG & Beasley NJ 2003 Intratumoral lymphatics and lymph node metastases in papillary thyroid carcinoma. Archives of Otolaryngology, Head & Neck Surgery 129 716-719.
15. Huang SM, Lee JC, Wu TJ & Chow NH 2001 Clinical relevance of vascular endothelial growth factor for thyroid neoplasms. World Journal of Surgery 25 302-306.
16. Hung CJ, Ginzinger DG, Zarnegar R, Kanauchi H, Wong MG, Kebebew E, Clark OH & Duh QY 2003 Expression of Vascular endothelial growth factor-C in benign and malignant thyroid tumors. Journal of Clinical Endocrinology and Metabolism 88 3694-3699.
17. Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H, Swartz M, Fukumura D, Jain RK & Alitalo K 1997 Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276 1423-1425.
18. Kayser L, Broholm H, Francis D, Perrild H, Olsen BE, Bendtzen K & Hoyer PE 1995 Immunocytochemical localisation of interleukin-1 alpha and interleukin-6 in thyroid tissues from patients with neoplastic or autoimmune thyroid disorders. Autoimmunity 20 75-82.
19. Kilicarslan AB, Ogus M, Arici C, Pestereli HE, Cakir & Karpuzoglu G 2003 Clinical importance of vascular endothelial growth factor (VEGF) for papillary thyroid carcinomas. APMIS 111 439-443.
20. Kim DS, McCabe CJ, Buchanan MA & Watkinson JC 2003 Oncogenes in thyroid cancer. Clinical Otolaryngology and Allied Sciences 28 386-395.
21. Klein M, Picard E, Vignaud JM, Marie B, Bresler L, Toussaint B, Weryha G, Duprez A & Leclere J 1999 Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. Journal of Endocrinology 161 41-49.
22. Klein M, Vignaud JM, Hennequin V, Toussaint B, Bresler L, Plenat F, Leclere J, Duprez A & Weryha G 2001 Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 86 656-658.
23. Lennard CM, Patel A, Wilson J, Reinhardt B, Tuman C, Fenton C, Blair E, Francis GL & Turtle RM 2001 Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery 129 552-558.
24. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM & Pagano M 1997 Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal cancer. Nature Medicine 3 231-234.
25. Nagura S, Katoh R, Miyagi E, Shibuya M & Kawaoi A 2001 Expression of vascular endothelial growth factor (VEGF) and VEGF receptor-1 (Flt-1) in Graves disease possibly correlated with increased vascular density. Human Pathology 32 10-17.
26. Nisato RE, Tille JC & Pepper MS 2003 Lymphangiogenesis and tumor metastasis. Thrombosis and Haemostasis 90 591-597.
27. Oh SJ, Jeltsch MM, Birkenhager R, McCarthy JE, Weich HA, Christ B, Alitalo K & Wilting J 1997 VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Developmental Biology 188 96-109.
28. Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR & Roberts JM 1997 Expression of cell-cycle regulators p27/Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nature Medicine 3 222-225.
29. Ristimaki A, Kirsi N, Enholm B, Joukov V & Alitalo K 1998 Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor. Journal of Biological Chemistry 273 8413-8418.
30. Rodriguez JM, Pinero A, Ortiz S, Moreno A, Sola J, Soria T, Robles R & Parrilla P 2000 Clinical and histological differences in anaplastic thyroid carcinoma. European Journal of Surgery 166 34-38.
31. Sato K, Yamazaki K, Shizume K, Kanaji Y, Obara T, Ohsumi K, Demura H, Yamaguchi S & Shibuya M 1995 Stimulation by thyroid-stimulating hormone and Grave's immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA expression in the rat thyroid in vivo. Journal of Clinical Invesigation 96 1295-1302.
32. Scollo C, Baudin E, Travagli JP, Caillou B, Bellon N, Leboulleux S & Schlumberger M 2003 Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 88 2070-2075.
33. Shingu K, Sugenoya A, Itoh N & Kato R 1994 Expression of basic fibroblast growth factor in thyroid disorders. World Journal of Surgery 18 500-505.
34. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Clafey K & Detmar M 2001 Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nature Medicine 7 192-198.
35. Smith-McCune KK & Weidner N 1994 Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Research 54 800-804.
36. Stewart M, Talks K, Leek R, Turley H, Pezzella F, Harris A & Gatter K 2002 Expression of angiogenic factors and hypoxia inducible factors HIF 1, HIF 2 and CA IX in non-Hodgkin's lymphoma. Histopathology 40 253-260.
37. Tanaka K, Kurebayashi J, Sonoo H, Otsuki T, Yamamoto Y, Ohkubo S, Yamamoto S & Shimozuma K 2002 Expression of vascular endothelial growth factor family messenger RNA in diseased thyroid tissues. Surgery Today 32 761-768.
38. Trojan L, Michel MS, Rensch F, Jackson DG, Alken P & Grobholz R 2004 Lymph and blood vessel architecture in benign and malignant prostatic tissue: lack of lymphangiogenesis in prostate carcinoma assessed with novel lymphatic marker lymphatic vessel endothelial hyaluronan receptor (LYVE-1). Journal of Urology 172 103-107.
39. Turley H, Scott PA, Watts VM, Bicknell R, Harris AL & Gatter KC 1998 Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1. Journal of Pathology 186 313-318.
40. Turner HE, Nagy Z, Gatter KC, Esiri MM, Harris AL & Wass JAH 2000 Angiogenesis in pituitary adenomas and the normal pituitary gland. Journal of Clinical Endocrinology and Metabolism 85 1159-1162.
41. Viglietto G, Romano A, Manzo G, Chiappetta G, Paoletti I, Califano D, Galati MG, Mauriello V, Bruni P, Lago CT et al. 1997 Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracilfed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization. Oncogene 15 2687-2698.
42. Vlodavsky I, Fridman R, Sullivan R, Sasse J & Klagsbrun M 1987 Aortic endothelial cells synthesize basic fibroblast growth factor which remains cell associated and platelet-derived growth factor-like protein which is secreted. Journal of Cellular Physiology 131 402-408.
43. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ & Holash J 2000 Vascular-specific growth factors and blood vessel formation. Nature 407 242-248.
44. Yu XM, Lo CY, Chan WF, Lam KY, Leung P & Luk JM 2005 Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases. Clinical Cancer Research 11 8063-8069.
45. Xie K, Wei D, Shi Q & Huang S 2004 Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine & Growth Factor Reviews 15 297-324.